CLXPF

Cybin Inc.

61 views8 min read

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Cybin
TORONTO, June 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved certain earn-out milestones for the period ... Read More...
18 views5 min read

Cybin Announces CDN$20 Million Bought Deal Offering

Cybin
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, Jan. 18, 2021 - Cybin Inc. (NEO: CYBN) ("Cybin" or the "Company"), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. ("... Read More...
Joint Venture104 views6 min read

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Cybin
HIGHLIGHTSUsing Kernel’s technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences. The absence of this data has been a limitation in the progression of new molecules targeting neurological disorders.Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal bra... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!